Genmab A/S Sponsored ADR $GMAB Shares Acquired by Dorsey Wright & Associates

Dorsey Wright & Associates grew its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 43.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 64,388 shares of the company’s stock after purchasing an additional 19,551 shares during the period. Dorsey Wright & Associates’ holdings in Genmab A/S were worth $1,728,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. CIBC Private Wealth Group LLC raised its stake in Genmab A/S by 291.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 616 shares during the period. Osaic Holdings Inc. boosted its stake in Genmab A/S by 37.8% in the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the period. V Square Quantitative Management LLC acquired a new position in Genmab A/S in the first quarter valued at approximately $34,000. NewEdge Advisors LLC grew its holdings in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its holdings in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock valued at $41,000 after purchasing an additional 780 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on GMAB shares. Weiss Ratings cut Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. Wolfe Research initiated coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 price target for the company. HC Wainwright increased their price objective on shares of Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Finally, BNP Paribas Exane raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.21.

Genmab A/S Stock Down 0.9%

Shares of Genmab A/S stock opened at $28.72 on Friday. The business’s fifty day moving average price is $26.62 and its two-hundred day moving average price is $28.42. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The company has a market capitalization of $17.91 billion, a P/E ratio of 21.76, a PEG ratio of 1.84 and a beta of 0.84. Genmab A/S Sponsored ADR has a 1-year low of $21.00 and a 1-year high of $35.43.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.